Related Experiment Video
Updated: May 13, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet therapy to prevent cardiovascular events and mortality in patients with intermittent claudication
Peng Foo Wong1, Lee-Yee Chong, Gerard Stansby
1Department of Vascular Surgery, James Cook University Hospital, Marton Road, Middlesbrough, Cleveland, TS4 3BW England. pwong23@hotmail.com
Clinical Question:
Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality?
Bottom Line:
In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Angina IV: Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation